Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
PM Kishida Orders 3 Ministers to Map Out Overall COVID-19 Response Plan
Japan’s new prime minister, Fumio Kishida, on October 4 instructed three ministers related to coronavirus responses to sketch out an overall plan on COVID-19 measures aimed at reinforcing the inoculation and healthcare delivery system as well as the testing scheme.…
To read the full story
Related Article
- New Digital, Administrative Reform Minister Set to Break Silos, Propel Healthcare Revamp
October 6, 2021
- Economic Security Chief Vows to Beef Up Vaccine Development, Manufacturing in Japan
October 6, 2021
- Master Plan on COVID-19 Measures to Be Compiled Relatively Soon: Response Minister
October 6, 2021
- New Vaccine Czar Hints Booster Program Could Start in December
October 6, 2021
- Transparency and Predictability Up for Discussion towards 2022 Drug Pricing Reform: New Minister
October 6, 2021
- New Health Minister Goto Vows to Protect Secure Healthcare System in FY2022 Reform
October 5, 2021
- Pharma Officials Air Hopes and Concerns for New LDP Leader, Eyes on MHLW Revamp
September 30, 2021
- All 4 Contenders in LDP Leadership Race Vow to Expand COVID-19 Measures
September 21, 2021
REGULATORY
- 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
- MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
- Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026
- Japan Grants Orphan Tag to Bayer, Incyte Drugs, and 12 Others
February 17, 2026
- Japan to Delist 387 Drugs from NHI Price List, Including Renivace
February 16, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…